Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$37.71 -1.2%	$37.12	$23.42 ▼ $62.58	$2.19B	0.87	844,455 shs	502,787 shs
CNTA Centessa Pharmaceuticals	$16.79 +1.4%	$15.70	$9.60 ▼ $19.09	$2.25B	1.47	1.03 million shs	632,847 shs
DNLI Denali Therapeutics	$15.27 -2.4%	$14.44	$10.57 ▼ $33.33	$2.23B	1.23	1.79 million shs	1.89 million shs
XNCR Xencor	$8.13 +1.0%	$8.29	$6.92 ▼ $27.24	$579.83M	0.82	743,533 shs	769,384 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	-2.81%	+7.74%	+15.57%	-17.86%
CNTA Centessa Pharmaceuticals	0.00%	-1.29%	-0.12%	+25.21%	+24.37%
DNLI Denali Therapeutics	0.00%	-1.42%	+13.62%	+9.38%	-37.52%
XNCR Xencor	0.00%	-3.33%	+1.88%	-5.24%	-53.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.4217 of 5 stars	3.4	2.0	4.3	4.2	0.8	1.9
CNTA Centessa Pharmaceuticals	2.5979 of 5 stars	3.5	1.0	0.0	3.5	2.5	0.6
DNLI Denali Therapeutics	4.2505 of 5 stars	3.6	1.0	4.7	4.2	3.3	0.0
XNCR Xencor	3.6496 of 5 stars	3.4	0.0	3.9	2.9	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	49.39% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$31.50	87.61% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.62	120.14% Upside
XNCR Xencor	2.75	Moderate Buy	$23.71	191.69% Upside

Current Analyst Ratings Breakdown

Latest XNCR, CNTA, DNLI, and AGIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/29/2025	CNTA Centessa Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$40.00
8/21/2025	XNCR Xencor	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $15.00
8/18/2025	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $30.00
8/12/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
8/7/2025	XNCR Xencor	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $27.00
8/7/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$31.00 ➝ $26.00
7/30/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
7/21/2025	CNTA Centessa Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00

(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	60.03	N/A	N/A	$27.02 per share	1.40
CNTA Centessa Pharmaceuticals	$6.85M	328.23	N/A	N/A	$3.05 per share	5.50
DNLI Denali Therapeutics	$330.53M	6.75	N/A	N/A	$8.53 per share	1.79
XNCR Xencor	$110.49M	5.25	N/A	N/A	$9.63 per share	0.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.43	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.79	N/A	N/A	N/A	N/A	-40.39%	-29.87%	11/11/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.80	N/A	N/A	N/A	N/A	-40.79%	-36.39%	11/5/2025 (Estimated)
XNCR Xencor	-$232.62M	-$2.40	N/A	N/A	N/A	-121.52%	-25.75%	-18.19%	11/5/2025 (Estimated)

Latest XNCR, CNTA, DNLI, and AGIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.38	-$0.03	-$0.38	$0.63 million	N/A
8/11/2025	Q2 2025	DNLI Denali Therapeutics	-$0.74	-$0.72	+$0.02	-$0.72	$5.64 million	N/A
8/6/2025	Q2 2025	XNCR Xencor	-$0.78	-$0.41	+$0.37	-$0.41	$22.59 million	$43.61 million
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
CNTA Centessa Pharmaceuticals	0.32	10.11	10.12
DNLI Denali Therapeutics	0.01	10.27	10.27
XNCR Xencor	N/A	5.34	5.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
CNTA Centessa Pharmaceuticals	82.01%
DNLI Denali Therapeutics	92.92%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.93%
CNTA Centessa Pharmaceuticals	7.09%
DNLI Denali Therapeutics	12.50%
XNCR Xencor	5.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.24 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.91 million	124.42 million	Optionable
DNLI Denali Therapeutics	430	146.21 million	127.94 million	Optionable
XNCR Xencor	280	71.32 million	67.59 million	Optionable

XNCR, CNTA, DNLI, and AGIO Headlines

Recent News About These Companies

161,149 Shares in Xencor, Inc. $XNCR Bought by Nuveen LLC

September 1 at 3:32 AM | marketbeat.com

Price T Rowe Associates Inc. MD Decreases Position in Xencor, Inc. $XNCR

August 30 at 4:22 AM | marketbeat.com

Invesco Ltd. Raises Holdings in Xencor, Inc. $XNCR

August 29 at 3:23 AM | marketbeat.com

Xencor to Participate at Upcoming Investor Conferences

August 27, 2025 | businesswire.com

Vanguard Group Inc. Trims Stake in Xencor, Inc. $XNCR

August 26, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Receives $23.71 Consensus Target Price from Brokerages

August 25, 2025 | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by Analysts

August 24, 2025 | marketbeat.com

Aberdeen Group plc Grows Holdings in Xencor, Inc. $XNCR

August 23, 2025 | marketbeat.com

Royal Bank Of Canada Lowers Xencor (NASDAQ:XNCR) Price Target to $15.00

August 23, 2025 | americanbankingnews.com

Xencor, Inc. $XNCR Stock Holdings Lifted by Public Sector Pension Investment Board

August 22, 2025 | marketbeat.com

Xencor price target lowered to $15 from $32 at RBC Capital

August 21, 2025 | msn.com

Q3 Earnings Estimate for Xencor Issued By Leerink Partnrs

August 11, 2025 | marketbeat.com

Wedbush Estimates Xencor's Q3 Earnings (NASDAQ:XNCR)

August 11, 2025 | marketbeat.com

William Blair Analysts Boost Earnings Estimates for Xencor

August 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.37 EPS

August 10, 2025 | marketbeat.com

Xencor (XNCR) Receives a Buy from Leerink Partners

August 9, 2025 | theglobeandmail.com

Xencor, Inc. (NASDAQ:XNCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

August 9, 2025 | finance.yahoo.com

Xencor (XNCR) Q2 Revenue Jumps 82%

August 9, 2025 | theglobeandmail.com

Xencor (NASDAQ:XNCR) Hits New 12-Month Low on Analyst Downgrade

August 8, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Given New $27.00 Price Target at Wells Fargo & Company

August 8, 2025 | marketbeat.com

Wedbush Lowers Xencor (NASDAQ:XNCR) Price Target to $26.00

August 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR, CNTA, DNLI, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$37.71 -0.47 (-1.23%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$37.72 +0.02 (+0.04%)

As of 08/29/2025 05:38 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Centessa Pharmaceuticals NASDAQ:CNTA

$16.79 +0.23 (+1.39%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$16.78 0.00 (-0.03%)

As of 08/29/2025 04:38 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Denali Therapeutics NASDAQ:DNLI

$15.27 -0.38 (-2.43%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$15.36 +0.09 (+0.59%)

As of 08/29/2025 06:02 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Xencor NASDAQ:XNCR

$8.13 +0.08 (+0.99%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$8.13 0.00 (0.00%)

As of 08/29/2025 06:43 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time